文献速递肿瘤 PET/CT骨显像与常规 SPECT

99mTc-MIP-1404 SPECT/CT 用于转移性前列腺癌患者:前列腺特异性膜抗原阳性病灶治疗相关纵向示踪剂摄取评估的观察者间与观察者内变异性

99mTc-MIP-1404 SPECT/CT for Patients With Metastatic Prostate Cancer: Interobserver and Intraobserver Variability in Treatment-Related Longitudinal Tracer Uptake Assessments of Prostate-Specific Membrane Antigen-Positive Lesions.
PubMed 文献 · Clin Nucl Med · 2020-01-01

研究分析 22 例转移性前列腺癌患者治疗前后共两次 99mTc-MIP-1404 SPECT/CT 扫描(平均间隔 10 个月),由 3 名独立观察者评估 96 个 PSMA 阳性病灶的纵向摄取变化。定量 SPECT/CT 的观察者间一致性(90.6%)显著高于视觉 SPECT/CT(76.0%)和平面显像(56.3%);观察者内一致性各方法均接近完美(κ=0.90–0.98),SPECT/CT 的阅片者信心高于平面显像(P<0.001)。

要点

  • 定量 SPECT/CT 评估 PSMA 阳性病灶纵向摄取变化的观察者间一致性为 90.6%,高于视觉 SPECT/CT 的 76.0% 和平面显像的 56.3%。
  • 定量 SPECT/CT 与视觉 SPECT/CT 间一致性为 85.1%,高于定量 SPECT/CT 与平面显像的 53.1% 及视觉 SPECT/CT 与平面显像的 54.9%。
  • 所有方法的观察者内一致性均接近完美,SPECT/CT 的阅片者信心高于平面显像(P<0.001)。

核心结论

  • 通过 SPECT/CT 定量评估 PSMA 阳性病灶纵向示踪剂摄取变化优于平面显像或 SPECT/CT 的视觉判读。
  • 与视觉评估相比,定量 SPECT/CT 具有高度可重复性,观察者间一致性接近完美且阅片者信心更高。

研究设计与样本

  • 研究纳入 22 例转移性前列腺癌患者,每例在治疗前后两个时间点接受 99mTc-MIP-1404 SPECT/CT 扫描,两次扫描平均间隔 10 个月。
  • 3 名独立观察者对共 96 个 PSMA 阳性转移灶(骨 69 个、淋巴结 22 个、内脏 3 个)或局部复发灶(n=2)进行平面显像和 SPECT/CT 的视觉评估,判断纵向示踪剂摄取变化。
  • 所有病灶依据视觉所见及定量 SPECT/CT 的 SUVpeak 分为消退、稳定或进展(进展为 SUVpeak 增加 >30%;消退为 SUVpeak 降低 <30%;其余为稳定)。

主要发现

  • 定量分析 PSMA 阳性病灶的观察者间一致性为 90.6%(95%CI 0.83%–0.96%),显著高于视觉 SPECT/CT 的 76.0%(95%CI 0.66%–0.84%)和平面显像的 56.3%(95%CI 0.46%–0.66%)。
  • 定量与视觉 SPECT/CT 聚合结果间一致性为 85.1%(95%CI 0.80%–0.89%),高于定量 SPECT/CT 与平面显像的 53.1%(95%CI 0.47%–0.59%)及视觉 SPECT/CT 与平面显像的 54.9%(95%CI 0.49%–0.61%)。
  • 96 个 PSMA 阳性病灶的视觉与定量分析中,不一致数从定量 SPECT/CT 的 9 个(9.4%)到平面显像的 42 个(43.8%)不等。
  • SPECT/CT 的总体阅片者信心高于平面显像(P<0.001)。
  • 观察者内一致性在所有方法中均接近完美:SPECT/CT 视觉 κ=0.94–0.97、定量 κ=0.94–0.98;平面显像 κ=0.90–0.94。

关键数值与推荐

  • 进展定义为 SUVpeak 增加 >30%;消退定义为 SUVpeak 降低 <30%;其余为稳定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tc-MIP-1404 is a SPECT-suitable prostate-specific membrane antigen (PSMA) ligand for detection of prostate cancer. In patients with metastatic prostate cancer, there are no data as yet on interobserver and intraobserver variability when assessing PSMA-positive lesions for longitudinal changes of tracer uptake. METHODS: Tc-MIP-1404 SPECT/CT scans of 22 patients with metastatic prostate cancer were analyzed, and each subject was imaged at 2 separate points in time, before and after treatment. Mean interval between scans was 10 months. Three independent observers visually assessed a total of 96 PSMA-positive metastases (bone, 69; lymph node, 22; viscera, 3) or local recurrences (n = 2) for longitudinal changes in tracer uptake on planar scintigraphy and SPECT/CT. All lesions were categorized as regressive, stable, or progressive based on visual findings and on peak SUV (SUVpeak) of quantitative SPECT/CT (progressive, >30% SUVpeak increase; regressive, <30% SUVpeak decrease; or stable, all others). RESULTS: Quantitative analysis of PSMA-positive lesions yielded significantly higher interobserver agreement (90.6%; 95% confidence interval [CI], 0.83%-0.96%) than visual assessments by either SPECT/CT (76.0%; 95% CI, 0.66%-0.84%) or planar scintigraphy (56.3%; 95% CI, 0.46%-0.66%). Intermethod comparison of aggregated results yielded significantly higher agreement between quantitative and visual SPECT/CT (85.1%; 95% CI, 0.80%-0.89%), as opposed to quantitative SPECT/CT and planar scintigraphy (53.1%; 95% CI, 0.47%-0.59%) or visual SPECT/CT and planar scintigraphy (54.9%; 95% CI, 0.49%-0.61%). In visual and quantitative analysis of 96 PSMA-positive lesions, the number of discrepancies ranged from 9 (9.4%) for quantitative SPECT/CT to 42 (43.8%) for planar scintigraphy. Overall reader confidence was higher for SPECT/CT than for planar scintigraphy (P < 0.001). Intraobserver agreement was near-perfect for all methods, whether SPECT/CT (visual, all κ = 0.94-0.97; quantitative κ = 0.94-0.98) or planar scintigraphy (all κ = 0.90-0.94). CONCLUSIONS: Quantitative evaluation of longitudinal change in tracer uptake by PSMA-positive lesions measured via SPECT/CT is superior to visual interpretation of images by planar scintigraphy or SPECT/CT. Compared with visual evaluation, quantitative SPECT/CT is highly reproducible, showing near-perfect agreement among observers and higher reader confidence.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Schmidkonz C, Atzinger A, Goetz TI, et al. 99mTc-MIP-1404 SPECT/CT for Patients With Metastatic Prostate Cancer: Interobserver and Intraobserver Variability in Treatment-Related Longitudinal Tracer Uptake Assessments of Prostate-Specific Membrane Antigen-Positive Lesions. Clin Nucl Med. 2020. PMID: 31876822. doi:10.1097/RLU.0000000000002880

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。